Trial Profile

A Phase Ib, Multi-Cohort, Open-Label, Multi-Center Clinical Trial to Evaluate the Efficacy and Safety of RC148 Injection as Monotherapy or Combination Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 27 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Pemetrexed (Primary) ; RC 148 (Primary)
Indications Non-small cell lung cancer
Focus Therapeutic Use
Sponsors RemeGen

21 Aug 2026 According to a Abbvie media release, data from this trial was presented at the 2026 World Conference on Lung Cancer (WCLC).
05 Mar 2026 Status changed from recruiting to active, no longer recruiting.
15 Jul 2025 Planned number of patients changed from 150 to 120.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com